Hangzhou Sino-US Huadong Medicine Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd.  have reached a strategic cooperation. The two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, targeting angiotensinogen (AGT) for the treatment of hypertension.

华东医药股份有限公司（SZ.000963）的全资子公司杭州中美华东医药有限公司与SynerK PharmaTech（苏州）有限公司达成了战略合作。双方将共同开发针对血管紧张素原（AGT）治疗高血压的小核酸（siRNA）药物SNK-2726。

Huadong Medicine has obtained the exclusive option, once exercised, for the right to develop, register, manufacture and commercialize the drug in Greater China.SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage. According to the agreement, the two parties will jointly develop SNK-2726 to a certain stage.

华东医药获得了在大中华区开发、注册、制造和商业化该药物的独家选择权。SynerK拥有SNK-2726的知识产权，目前正处于IND备案准备阶段。根据协议，双方将共同开发SNK-2726到一定阶段。

At the same time, Huadong Medicine obtains the exclusive option and may pay the exercise fee in the future to obtain the rights for exclusive development, registration, production and commercialization of SNK-2726 in Greater China. After Huadong Medicine exercises its rights, SynerK will also be entitled to receive subsequent R&D milestones and sales milestones, as well as tiered loyalties based on net sales after commercialization.Dr.

同时，华东医药获得独家选择权，并可能在未来支付行权费，以获得SNK-2726在大中华区的独家开发、注册、生产和商业化权利。在华东医药行使其权利后，SynerK还将有权获得后续的研发里程碑和销售里程碑，以及基于商业化后净销售额的分层忠诚度。。

Tao Lan, CEO of SynerK, said: 'We are very excited about the opportunity to cooperate with Huadong Medicine. Huadong Medicine's corporate philosophy of 'scientific research-based and patient-centered' coincides with our mission of 'changing patients' lives.' This cooperation further demonstrates the potential of SynerK's GalNexus siRNA platform.

SynerK首席执行官陶兰表示：“我们对有机会与华东医药合作感到非常兴奋。华东医药“以科研为基础，以患者为中心”的企业理念与我们“改变患者生活”的使命相吻合这种合作进一步证明了SynerK的GalNexus siRNA平台的潜力。

Through this 1+1>2 collaborative effort, we expect to accelerate the development of SNK-2726 and bring new treatment options to patients.'Lv Liang, chairman and general manager of Huadong Medicine, said: 'We are very pleased to reach this strategic cooperation with SynerK to develop the innovative siRNA.

通过这一1+1>2的合作努力，我们预计将加速SNK-2726的开发，并为患者带来新的治疗选择。”华东医药董事长兼总经理吕亮表示：“我们很高兴与SynerK达成战略合作，开发创新的siRNA。